Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Capital Lease Obligations

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Capital Lease Obligations

NTRB · NASDAQ
CompanyCapital Lease Obligations
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
0.00
N/AN/AN/A 
54.44M
-4.4%65.4%N/A
0.00
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
2.71M
-16.4%-13.6%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
14.74M
-11.0%-6.8%N/A
211.24K
-22.8%-25.4%N/A
13.40M
22.6%47.4%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
6.01M
-33.1%-14.3%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
2.98M
-34.8%-15.7%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
107.00K
-56.9%-35.9%N/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15